Catalent (NYSE:CTLT) Cut to “Sell” at StockNews.com

StockNews.com lowered shares of Catalent (NYSE:CTLT) from a hold rating to a sell rating in a research report released on Tuesday.

Several other research firms also recently issued reports on CTLT. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Robert W. Baird reissued a “neutral” rating and set a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. Finally, Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. One research analyst has rated the stock with a sell rating and seven have assigned a hold rating to the company’s stock. Based on data from MarketBeat.com, Catalent presently has a consensus rating of “Hold” and an average price target of $63.40.

Catalent Stock Down 0.3 %

Shares of CTLT opened at $63.07 on Tuesday. Catalent has a one year low of $37.03 and a one year high of $63.25. The company has a market capitalization of $11.45 billion, a P/E ratio of -27.91, a PEG ratio of 2.46 and a beta of 1.15. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. The business’s 50 day simple moving average is $60.25 and its 200-day simple moving average is $58.91.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The business’s revenue was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.10) earnings per share. As a group, sell-side analysts predict that Catalent will post 0.84 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the sale, the director now directly owns 10,835 shares of the company’s stock, valued at $646,849.50. This trade represents a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider David Mcerlane sold 1,994 shares of the company’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the transaction, the insider now owns 36,304 shares in the company, valued at $2,177,150.88. This represents a 5.21 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 5,114 shares of company stock valued at $305,931. Insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Catalent

Hedge funds and other institutional investors have recently modified their holdings of the stock. Brooklyn Investment Group bought a new stake in Catalent during the 3rd quarter valued at approximately $31,000. Sentry Investment Management LLC bought a new position in shares of Catalent during the 3rd quarter valued at about $53,000. Longfellow Investment Management Co. LLC grew its position in shares of Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after purchasing an additional 305 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. increased its holdings in shares of Catalent by 57.5% in the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company’s stock worth $72,000 after purchasing an additional 431 shares during the last quarter. Finally, Intact Investment Management Inc. purchased a new stake in shares of Catalent in the third quarter worth about $73,000.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.